
















The proliferative potential of eukaryotic cells is 
critically dependent upon the maintenance of 
functional telomeres, the protein-DNA complexes 
that cap the ends of chromosomes. A paper 
published in this issue of Aging describes that the 
telomere protein tankyrase 1 regulates DNA damage 
responses at telomeres.  
 
Telomeres are composed of TTAGGG repeats that 
associate with a six-protein telomere-specific complex 
termed shelterin, composed of telomeric-repeat binding 
factor 1 (TRF1), TRF2, TRF1 interacting protein 2 
(TIN2), protection of telomeres 1 (POT1), the POT1 
and TIN2 interacting protein TPP1 and the 
transcriptional repressor/activator protein RAP1 [1]. 
The shelterin complex comprises the physical termini of 
chromosomes and serves to prevent chromosomal ends 
from being recognized as DNA double-strand breaks 
(DSBs). The synthesis and maintenance of telomeric 
repeats are mediated by telomerase, a specialized 
ribonucleoprotein complex [2].  In the absence of 
telomerase, the failure of DNA polymerase to fully 
synthesize terminal ends of the lagging DNA strand 
leads to progressive telomere shortening with each 
round of replication.  In human somatic tissues, the 
strict down-regulation of telomerase accounts for the 
age-dependent decline in telomere lengths in somatic 
cells.  Studies have documented a decrease in telomere 
length in several human epithelial cell types, ranging 
from 50-100 bp per population doubling, for a total 
lifetime loss of approximately 2-4 kb [3].  This rate of 
telomere length attrition would be significant in long-
lived organisms such as humans. 
 
A large body of work in human cell culture systems and 
mouse models has documented the biological and 


















these consequences  relate to the  development of                   
premature aging and cancer [4]. Primary human cells 
have a limited replicative potential due to insufficient 
telomerase, resulting in the progressive shortening of 
telomeres with each cell division, eventually leading to 
the onset of replicative senescence.  Replicative 
senescence has been shown to be due to critically 
shortened (dysfunctional) telomeres activating the p53- 
dependent DNA damage response checkpoint. Rare 
cells that stochastically lose p53 or Rb function bypass 
this senescence checkpoint and progress towards 
cancer. These cells continue to shorten their telomeres, 
resulting in entry into a phase of rampant chromosomal 
instability termed crisis, characterized by end-to-end 
chromosomal fusions. Depending on how fused 
chromosomes are resolved, loss of heterozygocity of 
tumor suppressors and/or amplification of oncogenes 
could lead to a pro-cancer genotype.  Telomerase is 
reactivated in the majority of human carcinomas [5], 
supporting the hypothesis that telomerase reactivation is 
critically important for initiated cancer lesions to 
progress to frank malignancies, since it removes the 
short-telomere barriers that are inhibitory to tumor 
progression.  
 
A subset of human cancers utilizes a telomerase-
independent, alternative lengthening of telomeres 
(ALT) mechanisms to maintain telomere length [6]. 
Although the exact molecular mechanisms underlying 
ALT in mammalian tumors remain unclear, it is likely 
that ALT depends upon activation of the homologous 
recombination (HR) repair pathway.  The elegant 
cytogenetic technique Chromosome-Orientation (CO)-
FISH can be used to visualize HR within telomeric 
sequences [7,8]; stand-specific telomere probes are 
utilized to determine whether HR has taken place 
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chromatid exchange (T-SCE) is dramatically elevated in 
ALT cells [9-11], suggesting that hyper telomeric 
recombination may be a hallmark of this cell type. In 
addition, disrupting components of the shelterin 
complex, including TPP1/POT1 and TRF2 (in 
combination with DNA repair factors involved in the 
classical non-homologous end joining [C-NHEJ], Ku70 
and 53BP1) also results in elevated T-SCE [12-14]. 
These results suggest that aberrant telomere-telomere 
HR is actively repressed by components of the shelterin 
complex.  
 
In the current issue of AGING, Dregalla and colleagues 
extend upon these observations to reveal that removal of 
tankyrase 1, a telomere-associated poly(adenosine 
diphosphate [ADP]-ribose) polymerase (PARP), also 
results in increased frequencies of T-SCE [15]. 
Tankyrase 1 plays a critical role in regulating the 
quantity of TRF1 at telomeres, since tankyrase 1 
mediated poly(ADP-ribosyl)ation of TRF1 liberates it 
from telomeres [16,17]. Surprisingly, Dregalla et al. 
found that depletion of Tankyrase 1 also resulted in the 
rapid, proteosome-mediated degradation of DNA-PKcs, 
another major component of the NHEJ pathway. Other 
proteins involved in NHEJ, including Ku86 and ATM, 
were unaffected upon tankyrase 1 depletion, suggesting 
that DNA-PKcs stability specifically depends on 
tankyrase 1. Administering the small molecule PARP 
inhibitor XAV939 to cells also resulted in rapid 
depletion of DNA-PKcs, indicating specificity of the 
tankyrase 1 PARP domain for modulating DNA-PKcs 
stability. It is important to note that removal of DNA-
PKcs by itself did not result in increased T-SCE, 
suggesting tankyrase 1 suppresses T-SCE independent 
of its role in mediating DNA-PKcs stability. 
 
Why does aberrant recombination have to be repressed 
at telomeres? Recent data suggest that telomeres 
employ different shelterin components to prevent 
uncapped telomeres from engaging in distinct DNA 
damage signaling pathways. For example, TRF2 
specifically represses ATM signaling [18,19], and 
removal of TRF2 elicits C-NHEJ at telomeres that 
requires ATM, the Mre11-Rad50-NBS1 (MRN) 
complex and 53BP [20-23].  In contrast, TPP1-POT1 
specifically represses the ATR pathway [18-20]. 
Coupled with these observations, recent observations 
suggest that distinct DNA repair pathways at telomeres 
are also repressed by specific shelterin components. 
Removal of TRF2 resulted in the activation of Ligase 4-
dependent C-NHEJ-mediated end-to-end chromosome 
fusions.  In contrast, removal of TPP1-POT1 from 
telomeres resulted in increased T-SCEs and 
chromosome fusions mediated by a Ligase 4 indepen-
dent, alternative-NHEJ (A-NHEJ) pathway [14]. A-
NHEJ is a evolutionarily conserved repair pathway in 
which double strand break repair products display short 
tracks of microhomology at the repair junctions and the 
joining reaction utilizes DNA Ligase III [24]. Since 
DNA-PKcs is a component of C-NHEJ, it is likely that 
the elevated chromosome fusions observed by Dregalla 
et al. when tankyrase 1 is depleted (and DNA-PKcs 
levels are concomitantly reduced) is due to activation of 
A-NHEJ-mediated repair. In support of this notion, 
another recent report indicates that DNA-PKcs plays a 
role in repressing A-NHEJ at telomeres [25].  
 
Elevated T-SCEs has also been shown recently to 
accelerate entry into replicative senescence [26]. 
Increased T-SCE levels are observed in human cell lines 
in which the WRN protein has been depleted by siRNA, 
and in cells isolated from a premature aging mouse 
model of Werner Syndrome (WS), in which both the 
gene encoding the WRN helicase and telomerase are 
deleted [11,26,27].  It was previously thought that 
unequal T-SCEs could confer a proliferative advantage 
to cells that stochastically acquired the longer 
telomeres, enabling escape from cellular senescence [7]. 
However, in silico modeling revealed that increased T-
SCEs favored entry of telomerase null cells into 
replicative senescence [26]. Compared to cells without 
T-SCE, critically shortened telomeres in cells with 
elevated T-SCE appear earlier and in greater numbers 
[28]. This unexpected result suggests that the elevated 
T-SCE frequencies observed in ALT cells may reflect 
one mechanism of generating the high proportion of 
very short telomere lengths characteristic of this cell 
type [29]. Unequal T-SCE is however unlikely to 
endow ALT cells with unlimited replicative potential. 
Perhaps the elevated T-SCEs observed in ALT cells is 
symptomatic of a general heightened propensity 
towards recombination, but is not the cause of telomere 
lengthening. Additional mechanisms, including but not 
limited to a template copy mechanism initiated by short 
dysfunctional telomeres, might be responsible for 
generating new telomere DNA. 
 
The notion that elevated T-SCE promotes cellular 
senescence is likely to have interesting biological 
consequences. For example, in the setting of an intact 
p53 checkpoint, replicative senescence initiated by 
critically shortened telomeres has been shown to be as 
potent as apoptosis in suppressing tumorigenesis in vivo 
[30,31].  In these mouse models of cancer with 
dysfunctional telomeres, senescent markers were 
prominent in all tissues examined, suggesting that 
global activation of the senescence program potently 
inhibits tumor progression in vivo—thereby placing 
cellular senescence on an equal footing as apoptosis in 
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at a price, since signs of premature aging have been 
observed in some tumor-resistant mice bearing 
dysfunctional telomeres [30].  
 
Finally, the study by Dregalla and colleagues provides 
insight into targeting tankyrase 1 in the clinic.   
Manipulation of tankyrase 1 protein levels and/or 
inhibition of tankyrase 1 PARP activity would be 
expected to compromise C-NHEJ mediated DNA 
damage repair by DNA-PKcs. In a similar fashion to the 
therapeutic strategy of using PARP inhibitors against 
BRCA1/2 mutation carriers [32], a therapeutic strategy 
may be devised to combine radiation therapy with 
tankyrase 1 inhibition in BRCA1/2 associated breast 
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